Brian Kenneth Roberts
Known title: Sr VP, Clinic DevelopmentCIK: 0001829608
Brian Kenneth Roberts's purchase track record
How the stock did after each of Brian Kenneth Roberts's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
11
of 11 since May 4, 2022
Stock higher 6 months later
64%
3 months: 73%
Median 6-month return
+58.8%
3 months: +38.9%
Beat the S&P 500
64%
median +45.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/16/2025 | RZLT | $48K | +26.7% | +126.2% | +10.5% |
| 6/25/2025 | RZLT | $11K | +103.5% | -36.7% | +13.8% |
| 6/14/2024 | RZLT | $30K | +32.9% | +16.2% | +11.4% |
| 5/23/2024 | RZLT | $20K | +38.9% | +58.8% | +12.9% |
| 3/28/2024 | RZLT | $1K | +57.3% | +91.4% | +9.3% |
| 3/7/2024 | RZLT | $20K | +208.8% | +141.4% | +6.7% |
| 2/26/2024 | RZLT | $3K | +125.0% | +186.6% | +10.8% |
| 2/16/2024 | RZLT | $19K | +95.6% | +214.1% | +11.0% |
| 7/3/2023 | RZLT | $9K | -38.8% | -49.9% | +6.5% |
| 5/17/2022 | RZLT | $5K | -7.5% | -52.5% | -2.4% |
| 5/4/2022 | RZLT | $80K | -15.9% | -56.0% | -12.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RZLT | ▼ Sell | Tax Withholding | 3,062 | $15K | 7/2/2026 | View on chart |
| RZLT | ▼ Sell | Tax Withholding | 11,439 | $34K | 3/2/2026 | View on chart |
| RZLT | ▲ Buy | Open Market | 28,000 | $48K | 12/16/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 123,000 | $0 | 11/19/2025 | View on chart |
| RZLT | ▲ Buy | Open Market | 2,500 | $11K | 6/25/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 26,000 | $0 | 6/10/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 77,000 | $0 | 2/16/2025 | View on chart |
| RZLT | ▲ Buy | Open Market | 3,000 | $12K | 6/14/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 4,000 | $16K | 6/14/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 300 | $1K | 6/14/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 300 | $1K | 6/14/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 1,500 | $4K | 5/23/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 6,000 | $16K | 5/23/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 500 | $1K | 3/28/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 10,000 | $19K | 3/14/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 500 | $925 | 3/7/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 2,000 | $3K | 2/26/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 6,000 | $10K | 2/23/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 7,000 | $9K | 2/16/2024 | View on chart |
| RZLT | ▲ Buy | Open Market | 5,000 | $9K | 7/3/2023 | View on chart |
| RZLT | ▲ Buy | Open Market | 300 | $884 | 5/19/2022 | View on chart |
| RZLT | ▲ Buy | Open Market | 200 | $572 | 5/18/2022 | View on chart |
| RZLT | ▲ Buy | Open Market | 1,000 | $3K | 5/17/2022 | View on chart |
| RZLT | ▲ Buy | Open Market | 21,052 | $80K | 5/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results
Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results. Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.